{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:30:41Z","timestamp":1788316241709,"version":"build-2803163510"},"reference-count":15,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>We set out to study the relationship between different measures of glycemic variability and the rate of hypoglycemia in patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods:<\/jats:title>\n                    <jats:p>\n                      Data were pooled from three 24-week insulin trials including patients on twice-daily (BID) insulin lispro mix 75\/25 (75% insulin lispro protamine suspension, 25% insulin lispro) (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =805), daily (QD) insulin glargine (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =1,019), insulin lispro protamine suspension (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =353) (QD or BID), and insulin detemir (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =166) (QD or BID), all with continuation of prestudy oral antihyperglycemic medications. Glycemic variability measures were derived from seven-point self-monitored blood glucose profiles.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At baseline, mean (\u00b1SD) age was 56.9\u00b19.7 years, duration of type 2 diabetes was 9.5\u00b16.1 years, hemoglobin A1c (HbA1c) was 8.9\u00b11.1%, and 51.9% were male. Intra-day glucose coefficient of variation (CV), fasting blood glucose, intra-day minimum glucose and inter-day glucose CV at 24 weeks, and intra-day glucose CV at baseline were significantly correlated with the rate of hypoglycemia events between Weeks 12 to 24 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.05 for all measures).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Intra-day and inter-day glycemic variability is significantly associated with the risk of hypoglycemia in insulin-treated patients with type 2 diabetes, even after adjusting for mean glucose and HbA1c. The intra-day glycemic variability before starting insulin is significantly associated with the risk of hypoglycemia during insulin treatment, which points at treatment- and patient-related factors mediating this relationship.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2012.0099","type":"journal-article","created":{"date-parts":[[2012,10,26]],"date-time":"2012-10-26T11:27:30Z","timestamp":1351250850000},"page":"1008-1012","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":115,"title":["Rate of Hypoglycemia in Insulin-Treated Patients with Type 2 Diabetes Can Be Predicted from Glycemic Variability Data"],"prefix":"10.1177","volume":"14","author":[{"given":"Yongming","family":"Qu","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Jacober","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda L.","family":"Wolka","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Hans","family":"DeVries","sequence":"additional","affiliation":[{"name":"University of Amsterdam","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,11,1]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"1659","article-title":"Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data","volume":"79","author":"Cox DJ","year":"1994","unstructured":"Cox DJ, , Kovatchev BP, , Julian DM, , Gonder-Frederick LA, , Polonsky WH, , Schlundt DG, , Clarke WL. Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. J Clin Endocrinol Metab, 1994; 79:1659\u20131662.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0820-z"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0049"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.13.1445"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0021"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-2117"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02899.x"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01257.x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1085"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.19.9.644"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.10.2.225"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181cc4be9"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1684"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1013203451"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-9473(01)00065-2"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2012.0099","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2012.0099","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2012.0099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:18:38Z","timestamp":1777400318000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2012.0099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1089\/dia.2012.0099"],"URL":"https:\/\/doi.org\/10.1089\/dia.2012.0099","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}